Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003021711 | Prostate | Tumor | T cell differentiation | 61/3246 | 257/18723 | 5.30e-03 | 2.54e-02 | 61 |
GO:190134212 | Prostate | Tumor | regulation of vasculature development | 79/3246 | 348/18723 | 5.84e-03 | 2.71e-02 | 79 |
GO:00358217 | Prostate | Tumor | modulation of process of other organism | 29/3246 | 106/18723 | 6.60e-03 | 3.02e-02 | 29 |
GO:00516073 | Prostate | Tumor | defense response to virus | 62/3246 | 265/18723 | 6.92e-03 | 3.13e-02 | 62 |
GO:01405463 | Prostate | Tumor | defense response to symbiont | 62/3246 | 265/18723 | 6.92e-03 | 3.13e-02 | 62 |
GO:007121614 | Prostate | Tumor | cellular response to biotic stimulus | 58/3246 | 246/18723 | 7.43e-03 | 3.31e-02 | 58 |
GO:004576512 | Prostate | Tumor | regulation of angiogenesis | 77/3246 | 342/18723 | 7.92e-03 | 3.52e-02 | 77 |
GO:003105013 | Prostate | Tumor | dsRNA processing | 17/3246 | 54/18723 | 7.97e-03 | 3.52e-02 | 17 |
GO:007091813 | Prostate | Tumor | production of small RNA involved in gene silencing by RNA | 17/3246 | 54/18723 | 7.97e-03 | 3.52e-02 | 17 |
GO:00028316 | Prostate | Tumor | regulation of response to biotic stimulus | 74/3246 | 327/18723 | 8.03e-03 | 3.54e-02 | 74 |
GO:006096812 | Prostate | Tumor | regulation of gene silencing | 23/3246 | 81/18723 | 9.13e-03 | 3.93e-02 | 23 |
GO:004558011 | Prostate | Tumor | regulation of T cell differentiation | 37/3246 | 146/18723 | 9.18e-03 | 3.95e-02 | 37 |
GO:004482712 | Prostate | Tumor | modulation by host of viral genome replication | 8/3246 | 19/18723 | 1.00e-02 | 4.20e-02 | 8 |
GO:00705426 | Prostate | Tumor | response to fatty acid | 19/3246 | 64/18723 | 1.03e-02 | 4.31e-02 | 19 |
GO:00326408 | Prostate | Tumor | tumor necrosis factor production | 44/3246 | 181/18723 | 1.05e-02 | 4.38e-02 | 44 |
GO:00326808 | Prostate | Tumor | regulation of tumor necrosis factor production | 44/3246 | 181/18723 | 1.05e-02 | 4.38e-02 | 44 |
GO:00717068 | Prostate | Tumor | tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:19035558 | Prostate | Tumor | regulation of tumor necrosis factor superfamily cytokine production | 45/3246 | 186/18723 | 1.06e-02 | 4.42e-02 | 45 |
GO:190331125 | Skin | AK | regulation of mRNA metabolic process | 81/1910 | 288/18723 | 7.27e-18 | 8.61e-15 | 81 |
GO:001603228 | Skin | AK | viral process | 96/1910 | 415/18723 | 7.96e-15 | 3.37e-12 | 96 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZC3H12A | SNV | Missense_Mutation | novel | c.925N>C | p.Gly309Arg | p.G309R | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.698N>T | p.Ala233Val | p.A233V | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ZC3H12A | SNV | Missense_Mutation | novel | c.754N>A | p.Glu252Lys | p.E252K | Q5D1E8 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | | c.1711N>A | p.Ala571Thr | p.A571T | Q5D1E8 | protein_coding | tolerated(0.33) | benign(0.044) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1792N>G | p.Ser598Gly | p.S598G | Q5D1E8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1684N>A | p.Gly562Ser | p.G562S | Q5D1E8 | protein_coding | deleterious(0.04) | benign(0.219) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1457N>G | p.Ala486Gly | p.A486G | Q5D1E8 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ZC3H12A | SNV | Missense_Mutation | novel | c.574N>G | p.Pro192Ala | p.P192A | Q5D1E8 | protein_coding | tolerated(0.25) | probably_damaging(0.99) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.725C>T | p.Ser242Phe | p.S242F | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | insertion | Nonsense_Mutation | novel | c.971_972insTTGCTAAGAGTCCCCTAGCATCTTCCTGATGGTCTTTCTGCCTT | p.Glu324AspfsTer3 | p.E324Dfs*3 | Q5D1E8 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |